Collegium Pharmaceutical Inc’s recent filing unveils that its Director Freund John Gordon unloaded Company’s shares for reported $0.2 million on Jun 09 ’25. In the deal valued at $30.62 per share,6,601 shares were sold. As a result of this transaction, Freund John Gordon now holds 70,658 shares worth roughly $2.08 million.
Then, Freund John Gordon bought 6,601 shares, generating $202,148 in total proceeds.
Before that, Tupper Colleen sold 6,396 shares. Collegium Pharmaceutical Inc shares valued at $192,069 were divested by the EVP & Chief Financial Officer at a price of $30.03 per share. As a result of the transaction, Tupper Colleen now holds 156,667 shares, worth roughly $4.61 million.
Needham upgraded its Collegium Pharmaceutical Inc [COLL] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in late July from “a Neutral” to “a Buy”. Jefferies also remained covering COLL and has increased its forecast on June 07, 2024 with a “Buy” recommendation from previously “Hold” rating. Piper Sandler revised its rating on May 10, 2024. It rated COLL as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of COLL
On Tuesday, Collegium Pharmaceutical Inc [NASDAQ:COLL] saw its stock fall -0.91% to $29.44. Over the last five days, the stock has lost -3.06%. Collegium Pharmaceutical Inc shares have risen nearly 2.76% since the year began. Nevertheless, the stocks have fallen -7.86% over the past one year. While a 52-week high of $42.29 was reached on 01/10/25, a 52-week low of $23.23 was recorded on 04/10/25.
Levels Of Support And Resistance For COLL Stock
The 24-hour chart illustrates a support level at 29.15, which if violated will result in even more drops to 28.86. On the upside, there is a resistance level at 29.97. A further resistance level may holdings at 30.51.
